The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27876250 |
60 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH |
Jagiellonian University Medical College |
| 24960305 |
11 |
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. |
Merck Research Laboratories |
| 24794104 |
6 |
Serendipitous oxidation product of BIBN4096BS: a potent CGRP receptor antagonist. |
Bristol-Myers Squibb |
| 24405707 |
100 |
Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. |
Vertex Pharmaceuticals |
| 24332093 |
27 |
(E)-Alkenes as replacements of amide bonds: development of novel and potent acyclic CGRP receptor antagonists. |
Merck |
| 23993336 |
24 |
Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists. |
Bristol-Myers Squibb |
| 24900761 |
17 |
[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor. |
Merck Research Labortories |
| 23632269 |
9 |
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. |
Bristol-Myers Squibb R & D |
| 23402880 |
51 |
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2. |
Bristol-Myers Squibb Research & Development |
| 20097071 |
39 |
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine. |
Glaxosmithkline |
| 23153230 |
8 |
Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. |
Bristol-Myers Squibb Research & Development |
| 24900474 |
5 |
Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine. |
TBA |
| 22732695 |
26 |
Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor. |
Bristol-Myers Squibb R & D |
| 22727645 |
42 |
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1. |
Bristol-Myers Squibb Research & Development |
| 22607672 |
28 |
MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats. |
Merck Research Laboratories |
| 22429470 |
75 |
Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group. |
Bristol-Myers Squibb Research & Development |
| 22429471 |
64 |
Calcitonin gene-related peptide (CGRP) receptor antagonists: novel aspartates and succinates. |
Bristol-Myers Squibb Research & Development |
| 19010673 |
62 |
The discovery of highly potent CGRP receptor antagonists. |
Merck |
| 18039571 |
68 |
Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template. |
Merck Research Laboratories |
| | 6 |
Synthesis of -helix substituted analogs of calcitonin gene-related peptide |
TBA |
| 21251825 |
91 |
Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918. |
Merck Research Laboratories |
| 20850973 |
12 |
Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality. |
Merck |
| 20299218 |
52 |
Identification of potent, highly constrained CGRP receptor antagonists. |
Merck |
| 19818613 |
43 |
Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines. |
Merck Research Laboratories |
| 19703767 |
34 |
Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. |
Merck |
| 19577468 |
33 |
The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. |
Merck Research Laboratories |
| | 14 |
Quinine analogs as non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists |
TBA |
| 19467597 |
13 |
Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability. |
Bristol-Myers Squibb Research And Development |
| 18947992 |
88 |
Potent benzimidazolone-based CGRP receptor antagonists. |
Merck |
| 18665579 |
21 |
Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and effic |
Bristol-Myers Squibb Research & Development |
| 17929795 |
79 |
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). |
Merck Research Laboratories |
| 17616394 |
37 |
Caprolactams as potent CGRP receptor antagonists for the treatment of migraine. |
Merck Research Laboratories |
| 17319653 |
10 |
Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor. |
Université |
| 17027263 |
42 |
Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. |
Merck Research Laboratories |
| 16889959 |
86 |
Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine. |
Merck Research Laboratories |
| 16527483 |
20 |
Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. |
Department Of Medicinal Chemistry Merck |
| 16420047 |
17 |
Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. |
University Of Leipzig |
| 16161996 |
30 |
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist |
Boehringer Ingelheim Pharma |
| 9438028 |
63 |
From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor. |
Eth ZüRich |
| 1319490 |
27 |
Structure-activity study of hCGRP8-37, a calcitonin gene-related peptide receptor antagonist. |
Université |
| 27754592 |
15 |
Validation of flavonoids as potential dipeptidyl peptidase III inhibitors: Experimental and computational approach. |
Josip Juraj Strossmayer University Of Osijek |
| 27955923 |
12 |
Thymidine esters as substrate analogue inhibitors of angiogenic enzyme thymidine phosphorylase in vitro. |
University Of Karachi |
| 24257746 |
6 |
A L-lysine transporter of high stereoselectivity of the amino acid-polyamine-organocation (APC) superfamily: production, functional characterization, and structure modeling. |
Max Planck Institute Of Biophysics |
| | 35 |
SYNTHESIS AND PHARMACOKINETICS OF POTENT CARBAMATE HIV-1 PROTEASE INHIBITORS CONTAINING NOVEL HIGH AFFINITY HYDROXYETHYLAMINE ISOSTERES |
Eli Lilly |
Search and Browse
